The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Epigenetics Global Market Report 2024, the epigenetics market is expected to show promising growth in the forecast period.

The epigenetics market has experienced exponential growth, with the market size surging from $9 billion in 2023 to $10.91 billion in 2024, demonstrating an impressive compound annual growth rate (CAGR) of 21.2%. This growth in the historic period is attributed to increased research funding, a rise in the incidence of chronic diseases, personalized medicine, cancer research, and the aging population.

Key Figures:

• Market Size in 2023: $9 billion
• Projected Growth Rate (CAGR): 21.2%
• Forecasted Market Size in 2024: $10.91 billion

Future Landscape: Exponential Growth on the Horizon
The epigenetics market is poised for exponential growth in the next few years, reaching $23.86 billion in 2028, with a projected CAGR of 21.6%. Anticipated growth drivers in the forecast period include epigenetic drug development, epigenetics in environmental health, precision agriculture, regulatory support, and increased patient awareness and advocacy. Major trends in this period encompass epitranscriptomics, single-cell epigenomics, epigenetic editing, biomarkers, and research in aging and longevity, along with intriguing microbiome-epigenome interactions.

Projected Market Size in 2028: $23.86 billion

A Health Odyssey: Demand Propelled by Rising Diseases

The surge in cancer prevalence and other diseases is a primary catalyst for the growing demand in the epigenetics market. As per the European Commission’s Joint Research Centre, new cancer cases in the European Union and European Free Trade Association countries are expected to rise by 21.4%, from 2.8 million in 2020 to 3.4 million in 2040. Additionally, in the United States, approximately 659,000 people die of heart disease each year. The increasing prevalence of such diseases emphasizes the need for testing and understanding genetic modifications, driving the demand for epigenetics.

Key Data:

• European cancer cases expected to rise by 21.4%
• 659,000 deaths in the U.S. annually due to heart disease

Industry Leaders: Pioneering Companies in Epigenetics
Major companies operating in the epigenetics market play a pivotal role in driving innovation and research. Notable entities include Illumina Inc., Thermo Fisher Scientific, Merck Millipore, Abcam, Active Motif, Hologic Inc., Qiagen NV, and others. These companies contribute significantly to the advancement of the epigenetics field.

Key Companies:

• Illumina Inc.
• Thermo Fisher Scientific
• Merck Millipore
• Abcam
• Active Motif
• Hologic Inc.
• Qiagen NV

View More On The Epigenetics Market Report 2024 – https://www.thebusinessresearchcompany.com/report/epigenetics-global-market-report

AI’s Role: Analytics Revolutionizing Epigenetics Research
Artificial intelligence (AI)-driven analytics are becoming integral to the epigenetics market, offering a competitive edge. Notably, FOXO Technologies launched Bioinformatics Services in July 2023, revolutionizing epigenetic data analysis. Using innovative bioinformatic tools, FOXO aims to accelerate discoveries and enhance understanding of complex diseases through rapid and accurate data processing and interpretation.

Example:

• FOXO Technologies’ Bioinformatics Services

Strategic Moves: Chroma Medicine’s Acquisition for Epigenetic Editing

Chroma Medicine Inc., a U.S.-based biotechnology company, made strategic strides in November 2021 by acquiring Epsilen Bio for $125 billion. This acquisition bolsters Chroma Medicine’s epigenetic editing capabilities, enhancing its position in the market. Epsilen Bio, an Italy-based biotechnology company, specializes in transformative therapies through targeted epigenetic silencing of genes.

Key Acquisition:

• Chroma Medicine Inc. acquires Epsilen Bio for $125 billion (November 2021)

Market Segmentation: Decoding the Epigenetics Landscape
Understanding the epigenetics market requires insights into its segmentation. The market is categorized based on product types (reagents, enzymes, instruments, kits), technologies (DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microRNA modification, chromatin structures), applications (oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases, and others), and end-users (academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations, and others).

Market Segmentation:

1. By Product:
   • Reagents
   • Enzymes
   • Instruments
   • Kits
2. By Technology:
   • DNA Methylation
   • Histone Methylation
   • Histone Acetylation
   • Large Noncoding RNA
   • MicroRNA Modification
   • Chromatin Structures
3. By Application:
   • Oncology
   • Metabolic Diseases
   • Developmental Biology
   • Immunology
   • Cardiovascular Diseases
   • Other Applications
4. By End-User:
   • Academic and Research Institutes
   • Pharmaceutical and Biotechnology Companies
   • Contract Research Organizations
   • Other End Users

Regional Dynamics: North America Leads, Asia-Pacific Grows
In 2023, North America emerged as the largest region in the epigenetics market. Looking ahead, Asia-Pacific is expected to be the fastest-growing region during the forecast period, showcasing the global nature of the market’s evolution.

Regional Insights:

• North America (2023): Largest market
• Asia-Pacific: Fastest-growing region

In conclusion, the epigenetics market’s exponential growth is fueled by an increased understanding of diseases, technological advancements, and strategic acquisitions. As the field evolves, it holds the promise of transforming healthcare and our understanding of genetic and epigenetic influences on health and diseases.

Request A Sample Of The Global Epigenetics Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=7070&type=smp